4-(3-哒嗪基)吗啉 | 27464-01-3

• 分子结构分类: 有机化合物 - 有机氮化合物
• 中文名称: 4-(3-哒嗪基)吗啉
• 英文名称: 4-(pyridazin-3-yl)morpholine
• 英文别名: 3-Morpholino-pyridazin；4-pyridazin-3-ylmorpholine
• CAS: 27464-01-3
• 化学式: C₈H₁₁N₃O
• 分子量: 165.195
• InChiKey: WLDKNDQFNZDHEA-UHFFFAOYSA-N

物化性质

• 沸点：
  368.5±32.0 °C(Predicted)
• 密度：
  1.186±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -0.1
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  38.2
• 氢给体数：
  0
• 氢受体数：
  4

安全信息

• 海关编码：
  2934999090

反应信息

• 作为反应物：
  描述：

  4-(3-哒嗪基)吗啉 在 palladium diacetate 、 碳酸氢钠 、 caesium carbonate 、 4,5-双二苯基膦-9,9-二甲基氧杂蒽 、 hydroxylamine-O-sulfonic acid 作用下， 以 1,4-二氧六环 、 水 为溶剂， 反应 19.0h， 生成 3-((4-(2-cyclopropyl-6-morpholinopyrazolo[1,5-b]pyridazin-3-yl)pyrimidin-2-yl)amino)benzonitrile
  参考文献：
  名称：

  Selectivity and Physicochemical Optimization of Repurposed Pyrazolo[1,5-b]pyridazines for the Treatment of Human African Trypanosomiasis

  摘要：

  From a high-throughput screen of 42 444 known human kinases inhibitors, a pyrazolo[1,5-b]pyridazine scaffold was identified to begin optimization for the treatment of human African trypanosomiasis. Previously reported data for analogous compounds against human kinases GSK-3 beta, CDK-2, and CDK-4 were leveraged to try to improve the selectivity of the series, resulting in 23a which showed selectivity for T. b. brucei over these three human enzymes. In parallel, properties known to influence the absorption, distribution, metabolism, and excretion (ADME) profile of the series were optimized resulting in 20g being progressed into an efficacy study in mice. Though 20g showed toxicity in mice, it also demonstrated CNS penetration in a PK study and significant reduction of parasitemia in four out of the six mice.

  DOI：

  10.1021/acs.jmedchem.9b01741
• 作为产物：
  描述：

  4-(6-氯哒嗪-3-基)吗啉 在 palladium on activated charcoal 氢气 作用下， 以 甲醇 、 水 为溶剂， 生成 4-(3-哒嗪基)吗啉
  参考文献：
  名称：

  Bellasio; Parravicini; Testa, Farmaco, Edizione Scientifica, 1969, vol. 24, # 11, p. 919 - 929

  摘要：

  DOI：

文献信息

• A Method for the Reductive Scission of Heterocyclic Thioethers
  作者：Thomas H. Graham、Wensheng Liu、Dong-Ming Shen

  DOI：10.1021/ol2026813

  日期：2011.12.2

  substituent at the 2-position relative to a ring heteroatom. The convenient and straightforward method is demonstrated with reactants which are not compatible with the standard Raney nickel conditions such as sulfides, sulfones, and thiophenes. In addition, benzyl esters, benzyl amides, and benzyl carbamates are tolerated by the reductive reaction conditions.

  本发明描述了一种温和的，化学选择性的并且通常是高产率的用于还原性切割杂环硫醚的方法。合适的杂环在相对于环杂原子的2-位具有硫醚取代基。用与标准阮内镍条件不兼容的反应物（例如硫化物，砜和噻吩）证明了这种方便，直接的方法。另外，还原反应条件容许苄基酯，苄基酰胺和氨基甲酸苄酯。
• BENZOYL-PIPERIDINE DERIVATIVES AS DUAL MODULATORS OF THE 5-HT2A AND D3 RECEPTORS
  申请人：Gobbi Luca

  公开号：US20120004208A1

  公开（公告）日：2012-01-05

  The present invention relates to compounds of the general formula as dual modulators of the 5-HT 2a and D 3 receptors useful against CNS disorders, wherein A, R 1 , R 2 , n, p, q and r are as defined in the specification.

  本发明涉及一般式化合物作为5-HT2a和D3受体的双重调节剂，对中枢神经系统疾病有用，其中A、R1、R2、n、p、q和r如规范中所定义。
• Synthesis and evaluation of pyrazolo[1,5-b]pyridazines as selective cyclin dependent kinase inhibitors
  作者：Kirk L. Stevens、Michael J. Reno、Jennifer B. Alberti、Daniel J. Price、Laurie S. Kane-Carson、Victoria B. Knick、Lisa M. Shewchuk、Anne M. Hassell、James M. Veal、Stephen T. Davis、Robert J. Griffin、Michael R. Peel

  DOI：10.1016/j.bmcl.2008.09.069

  日期：2008.11

  A novel series of pyrazolo[1,5-b]pyridazines have been synthesized and identified as cyclin dependant kinase inhibitors potentially useful for the treatment of solid tumors. Modification of the hinge-binding amine or the C(2)- and C(6)-substitutions on the pyrazolopyridazine core provided potent inhibitors of CDK4 and demonstrated enzyme selectivity against VEGFR-2 and GSK3beta.
• UV absorbing and photostabilizing agents and compositions and external preparation for skin
  申请人：SHISEIDO COMPANY LIMITED

  公开号：EP1266651B1

  公开（公告）日：2006-09-06
• DI-AMINO-SUBSTITUTED HETEROCYCLIC COMPOUNDS AND METHODS OF USE
  申请人：Amgen Inc.

  公开号：EP2057133B1

  公开（公告）日：2014-08-20